Insight

Sep 13, 2024, 09:31

WCLC24 Highlights by Oncology Brothers

Oncology Brothers shared on X:

“WCLC24 Highlights Community Oncology:

HARMONi2 in mNSCLC
CM77TvsCM816 resectable NSCLC
TROPIONLung01 in 2L mNSCLC
SKIPPirr: AEs for Amivantamab
TNM staging: 9th Ed
Personal highlights

WCLC24

1. HARMONi2: 1L ivonescimab (PD1/VEGF bispecific) mNSCLC PDL1 ≥ 1% vs Pembro alone.

mPFS of 11.14 vs 5.8 months
Increased PFS for PDL1 ≥ 50% (HR: 0.46)
Increased PFS for PDL1 1-49% (HR: 0.54), but Standard of Care is Pembro + Chemo (no single agent Pembro)
China only study, will need global study

WCLC24

2. CM816 vs CM77T: NeoAdjuvant Chemo + IO vs PeriOperative Chemo + IO —> Cut —> PostOperative IO (exploratory analysis).

No head-to-head trial to appreciate the true benefit of post-operative IO.
Benefit of PostOperative IO mainly in patients with no pathological complete response and/or PDL1 < 1%.

WCLC24

3. TROPIONLung01: 2L and beyond DatoDXd vs Docetaxel for mNSCLC

All comers: median PFS 4.4 vs 3.7 months and median OS 12.9 vs 11.8 months
Median OS ‘did not reach statistical significance.’ Docetaxel remains Standard of Care.
Non-Small Cell Lung Cancer: median PFS 5.5 vs 3.6 months. Median OS 14.6 vs 12.3 months (HR 0.84)
Grade 3 or greater adverse events better with DatoDXd

WCLC24

4. SKIPPirr: Premedication to reduce Amivantamab-associated infusion reactions. Dexamethasone 8 mg twice daily on Days -2, -1, and 1 dose on Cycle 1 Day 1:

Reduced infusion reactions with prophylactic dexamethasone.
Small study. Subcutaneous formulation is pending approval.
Prophylactic dexamethasone to be used for patients receiving Amivantamab!

WCLC24

5. Proposed 9th Edition during WCLC23 but now part of our practice.

N1 disease = at least Stage IIA, but some N2 disease can be Stage IIB. N2 is now categorized as N2a (single station) or N2b (multi-station).
M1c1 vs M1c2

WCLC24

6. Personal Highlights: Seeing Jill Feldman, Amy C. Moore, and colleagues (fellows, students, residents, and thoracic oncologists) from around the world, and moderating a session with phenomenal faculty focusing on Standard of Care and research from WCLC24 in lung cancer.

WCLC24

Source: Oncology Brothers/X

More posts featuring WCLC24 on oncodaily.com
For other posts featuring Oncology Brothers click here.

Drs. Rohit Gosain and Rahul Gosain (aka Oncology Brothers), are medical oncologists/hematologists. Through their social media platforms like X/Twitter, they actively engage with their audience. With their own YouTube channel and podcast, they provide accessible resources for cancer patients and their families.

Additionally, their participation in live conferences ensures that cancer patients receive the best care closer to home, reflecting their commitment to advancing oncology and improving patient outcomes through education and outreach.